{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:17:06Z","timestamp":1789121826119,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001775","name":"University of Technology Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001775","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ovarian cancer (OC) remains difficult to detect at an early stage, and current screening approaches using CA125 and transvaginal ultrasonography have not demonstrated sufficient benefit for population screening. DNA methylation is a promising biomarker class because epigenetic alterations may arise early in tumourigenesis, can be detected in circulating cell-free DNA (cfDNA), and may provide tissue-of-origin information. This review critically evaluates recent evidence on DNA methylation biomarkers for early OC detection. PubMed\/MEDLINE, Web of Science, and Scopus were searched for studies published between January 2020 and September 2025, supplemented by selected earlier studies of biological or methodological relevance. Evidence was synthesised across single-gene biomarkers, multi-locus panels, genome-wide signatures, assay platforms, and machine-learning classifiers, with emphasis on early-stage performance, histological representation, comparator populations, analytical methodology, and validation design. Single-gene markers such as BRCA1, RASSF1A, OPCML, HOXA9, and HIC1 show variable performance, while multi-gene and classifier-based approaches generally provide stronger discrimination. However, many studies remain limited by retrospective case\u2013control designs, small FIGO stage I\u2013II subsets, predominance of serous disease, and insufficient prospective validation. Integration with CA125 may improve sensitivity but can reduce specificity, which is critical in low-prevalence screening. Clinical translation will therefore require minimal and reproducible methylation signatures, standardised low-input cfDNA workflows, rigorous external validation, and prospective longitudinal evaluation in intended-use populations.<\/jats:p>","DOI":"10.1007\/s11033-026-12750-6","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:12:10Z","timestamp":1789117930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["DNA methylation biomarkers for early detection of ovarian cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Jeremy Yuan-Sheng","family":"Leow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Choon-Si","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Shin-Yee","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long Chiau","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toong Lam","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bey Hing","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"12750_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3892\/ijo.2024.5650","volume":"64","author":"M Fu","year":"2024","unstructured":"Fu M, Deng F, Chen J et al (2024) Current data and future perspectives on DNA methylation in ovarian cancer (Review). Int J Oncol 64:62. https:\/\/doi.org\/10.3892\/ijo.2024.5650","journal-title":"Int J Oncol"},{"key":"12750_CR2","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ygyno.2022.03.018","volume":"165","author":"LM Marinelli","year":"2022","unstructured":"Marinelli LM, Kisiel JB, Slettedahl SW et al (2022) Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility. Gynecol Oncol 165:568\u2013576. https:\/\/doi.org\/10.1016\/j.ygyno.2022.03.018","journal-title":"Gynecol Oncol"},{"key":"12750_CR3","doi-asserted-by":"publisher","first-page":"863541","DOI":"10.3389\/fendo.2022.863541","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Huang Z, Li B et al (2022) The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer. Front Endocrinol 13:863541. https:\/\/doi.org\/10.3389\/fendo.2022.863541","journal-title":"Front Endocrinol"},{"key":"12750_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"12750_CR5","doi-asserted-by":"publisher","first-page":"101871","DOI":"10.1016\/j.mcp.2022.101871","volume":"66","author":"A Balla","year":"2022","unstructured":"Balla A, Bhak J, Bir\u00f3 O (2022) The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer. Mol Cell Probes 66:101871. https:\/\/doi.org\/10.1016\/j.mcp.2022.101871","journal-title":"Mol Cell Probes"},{"key":"12750_CR6","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3892\/etm.2022.11351","volume":"23","author":"R Mogos","year":"2022","unstructured":"Mogos R, Popovici R, Tanase A et al (2022) New approaches in ovarian cancer based on genetics and carcinogenesis hypotheses (Review). Exp Ther Med 23:423. https:\/\/doi.org\/10.3892\/etm.2022.11351","journal-title":"Exp Ther Med"},{"key":"12750_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13148-023-01440-w","volume":"15","author":"SK Terp","year":"2023","unstructured":"Terp SK, Stoico MP, Dybk\u00e6r K, Pedersen IS (2023) Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review. Clin Epigenetics 15:24. https:\/\/doi.org\/10.1186\/s13148-023-01440-w","journal-title":"Clin Epigenetics"},{"key":"12750_CR8","doi-asserted-by":"publisher","first-page":"12041","DOI":"10.3390\/ijms231912041","volume":"23","author":"R Zhang","year":"2022","unstructured":"Zhang R, Siu MKY, Ngan HYS, Chan KKL (2022) Molecular Biomarkers for the Early Detection of Ovarian Cancer. Int J Mol Sci 23:12041. https:\/\/doi.org\/10.3390\/ijms231912041","journal-title":"Int J Mol Sci"},{"key":"12750_CR9","doi-asserted-by":"publisher","first-page":"107327482412555","DOI":"10.1177\/10732748241255548","volume":"31","author":"Y Gao","year":"2024","unstructured":"Gao Y, Zhou N, Liu J (2024) Ovarian Cancer Diagnosis and Prognosis Based on Cell-Free DNA Methylation. Cancer Control 31:10732748241255548. https:\/\/doi.org\/10.1177\/10732748241255548","journal-title":"Cancer Control"},{"key":"12750_CR10","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3390\/cancers13040838","volume":"13","author":"XM Guo","year":"2021","unstructured":"Guo XM, Miller H, Matsuo K et al (2021) Circulating Cell-Free DNA Methylation Profiles in the Early Detection of Ovarian Cancer: A Scoping Review of the Literature. Cancers 13:838. https:\/\/doi.org\/10.3390\/cancers13040838","journal-title":"Cancers"},{"key":"12750_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12958-021-00860-8","volume":"19","author":"F Yang","year":"2021","unstructured":"Yang F, Tang J, Zhao Z et al (2021) Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer. Reprod Biol Endocrinol 19:178. https:\/\/doi.org\/10.1186\/s12958-021-00860-8","journal-title":"Reprod Biol Endocrinol"},{"key":"12750_CR12","doi-asserted-by":"publisher","first-page":"113674","DOI":"10.1016\/j.biopha.2022.113674","volume":"155","author":"D Bisht","year":"2022","unstructured":"Bisht D, Arora A, Sachan M (2022) Role of DNA De-methylation intermediate \u20185-hydroxymethylcytosine\u2019 in ovarian cancer management: A comprehensive review. Biomed Pharmacother 155:113674. https:\/\/doi.org\/10.1016\/j.biopha.2022.113674","journal-title":"Biomed Pharmacother"},{"key":"12750_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12935-023-03074-7","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu C, Tang H, Hu N, Li T (2023) Methylomics and cancer: the current state of methylation profiling and marker development for clinical care. Cancer Cell Int 23:242. https:\/\/doi.org\/10.1186\/s12935-023-03074-7","journal-title":"Cancer Cell Int"},{"key":"12750_CR14","doi-asserted-by":"publisher","first-page":"1430294","DOI":"10.3389\/freae.2024.1430294","volume":"2","author":"X Xu","year":"2024","unstructured":"Xu X, Guo Y, Liu M et al (2024) Advancements in the clinical application of gene methylation for early cancer detection. Front Epigenetics Epigenomics 2:1430294. https:\/\/doi.org\/10.3389\/freae.2024.1430294","journal-title":"Front Epigenetics Epigenomics"},{"key":"12750_CR15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu MC, Oxnard GR, Klein EA et al (2020) Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol 31:745\u2013759. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.011","journal-title":"Ann Oncol"},{"key":"12750_CR16","doi-asserted-by":"publisher","first-page":"101666","DOI":"10.1016\/j.xcrm.2024.101666","volume":"5","author":"G Li","year":"2024","unstructured":"Li G, Zhang Y, Li K et al (2024) Transformer-based AI technology improves early ovarian cancer diagnosis using cfDNA methylation markers. Cell Rep Med 5:101666. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101666","journal-title":"Cell Rep Med"},{"key":"12750_CR17","doi-asserted-by":"publisher","first-page":"20910","DOI":"10.1038\/s41598-025-05460-9","volume":"15","author":"J Gonzalez Bosquet","year":"2025","unstructured":"Gonzalez Bosquet J, Wagner VM, Russo D et al (2025) Identifying ovarian cancer with machine learning DNA methylation pattern analysis. Sci Rep 15:20910. https:\/\/doi.org\/10.1038\/s41598-025-05460-9","journal-title":"Sci Rep"},{"key":"12750_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12935-021-02136-y","volume":"21","author":"W Xie","year":"2021","unstructured":"Xie W, Sun H, Li X et al (2021) Ovarian cancer: epigenetics, drug resistance, and progression. Cancer Cell Int 21:434. https:\/\/doi.org\/10.1186\/s12935-021-02136-y","journal-title":"Cancer Cell Int"},{"key":"12750_CR19","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/jnci\/djaa070","volume":"112","author":"RD Kalachand","year":"2020","unstructured":"Kalachand RD, Stordal B, Madden S et al (2020) BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. JNCI J Natl Cancer Inst 112:1190\u20131203. https:\/\/doi.org\/10.1093\/jnci\/djaa070","journal-title":"JNCI J Natl Cancer Inst"},{"key":"12750_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13148-024-01787-8","volume":"16","author":"M Panagopoulou","year":"2024","unstructured":"Panagopoulou M, Panou T, Gkountakos A et al (2024) BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine. Clin Epigenetics 16:178. https:\/\/doi.org\/10.1186\/s13148-024-01787-8","journal-title":"Clin Epigenetics"},{"key":"12750_CR21","doi-asserted-by":"publisher","first-page":"719056","DOI":"10.3389\/fmolb.2021.719056","volume":"8","author":"A Singh","year":"2021","unstructured":"Singh A, Gupta S, Sachan M (2021) Evaluation of the Diagnostic Potential of Candidate Hypermethylated Genes in Epithelial Ovarian Cancer in North Indian Population. Front Mol Biosci 8:719056. https:\/\/doi.org\/10.3389\/fmolb.2021.719056","journal-title":"Front Mol Biosci"},{"key":"12750_CR22","doi-asserted-by":"publisher","first-page":"117955492513405","DOI":"10.1177\/11795549251340531","volume":"19","author":"A Gonc","year":"2025","unstructured":"Gonc A, Sukruoglu Erdogan O, Kilic Erciyas S et al (2025) CYB5R4 Gene Methylation as a Potential Epigenetic Marker for Ovarian Cancer. Clin Med Insights Oncol 19:11795549251340531. https:\/\/doi.org\/10.1177\/11795549251340531","journal-title":"Clin Med Insights Oncol"},{"key":"12750_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12957-025-03957-1","volume":"23","author":"S Zhou","year":"2025","unstructured":"Zhou S, Yin H, Yan L et al (2025) ctDNA methylation profiling reveals NBL1 as a promising biomarker for early ovarian cancer screening. World J Surg Oncol 23:305. https:\/\/doi.org\/10.1186\/s12957-025-03957-1","journal-title":"World J Surg Oncol"},{"key":"12750_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/ijc.34757","volume":"154","author":"C Herzog","year":"2024","unstructured":"Herzog C, Jones A, Evans I et al (2024) Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case\u2010control study and an ovarian cancer screening trial. Int J Cancer 154:679\u2013691. https:\/\/doi.org\/10.1002\/ijc.34757","journal-title":"Int J Cancer"},{"key":"12750_CR25","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1158\/1055-9965.EPI-20-1057","volume":"29","author":"RC Bast","year":"2020","unstructured":"Bast RC, Lu Z, Han CY et al (2020) Biomarkers and Strategies for Early Detection of Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 29:2504\u20132512. https:\/\/doi.org\/10.1158\/1055-9965.EPI-20-1057","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"12750_CR26","doi-asserted-by":"publisher","first-page":"188941","DOI":"10.1016\/j.bbcan.2023.188941","volume":"1878","author":"S Peng","year":"2023","unstructured":"Peng S, Zhang X, Wu Y (2023) Potential applications of DNA methylation testing technology in female tumors and screening methods. Biochim Biophys Acta BBA - Rev Cancer 1878:188941. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188941","journal-title":"Biochim Biophys Acta BBA - Rev Cancer"},{"key":"12750_CR27","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1101\/gr.266551.120","volume":"31","author":"R Vaisvila","year":"2021","unstructured":"Vaisvila R, Ponnaluri VKC, Sun Z et al (2021) Enzymatic methyl sequencing detects DNA methylation at single-base resolution from picograms of DNA. Genome Res 31:1280\u20131289. https:\/\/doi.org\/10.1101\/gr.266551.120","journal-title":"Genome Res"},{"key":"12750_CR28","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/s41587-023-02034-w","volume":"42","author":"Q Dai","year":"2024","unstructured":"Dai Q, Ye C, Irkliyenko I et al (2024) Ultrafast bisulfite sequencing detection of 5-methylcytosine in DNA and RNA. Nat Biotechnol 42:1559\u20131570. https:\/\/doi.org\/10.1038\/s41587-023-02034-w","journal-title":"Nat Biotechnol"},{"key":"12750_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/15592294.2021.1896984","volume":"17","author":"J Huang","year":"2022","unstructured":"Huang J, Soupir AC, Wang L (2022) Cell-free DNA methylome profiling by MBD-seq with ultra-low input. Epigenetics 17:239\u2013252. https:\/\/doi.org\/10.1080\/15592294.2021.1896984","journal-title":"Epigenetics"},{"key":"12750_CR30","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3390\/cancers14122885","volume":"14","author":"JM Liberto","year":"2022","unstructured":"Liberto JM, Chen S-Y, Shih I-M et al (2022) Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review. Cancers 14:2885. https:\/\/doi.org\/10.3390\/cancers14122885","journal-title":"Cancers"},{"key":"12750_CR31","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1200\/JCO.2023.41.16_suppl.3070","volume":"41","author":"W Liang","year":"2023","unstructured":"Liang W, Wang B, Tao J et al (2023) A machine learning\u2013based multidimensional model integrating clinical, radiomics, and cell-free DNA methylation biomarkers for the classification of pulmonary nodules. J Clin Oncol 41:3070\u20133070. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3070","journal-title":"J Clin Oncol"},{"key":"12750_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ygyno.2022.07.008","volume":"167","author":"N Li","year":"2022","unstructured":"Li N, Zhu X, Nian W et al (2022) Blood-based DNA methylation profiling for the detection of ovarian cancer. Gynecol Oncol 167:295\u2013305. https:\/\/doi.org\/10.1016\/j.ygyno.2022.07.008","journal-title":"Gynecol Oncol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12750-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12750-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12750-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:12:11Z","timestamp":1789117931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12750-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12750"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12750-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is a review and does not report any original data involving human participants or animals. Therefore, ethical approval was not required.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have reviewed and approved the final version of the manuscript and consent to its submission for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1562"}}